Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers
- 8 August 2022
- journal article
- review article
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 29 (17) , 2163-2172
Abstract
: Since the introduction of anthracyclines into clinical practice in the 1960s, chemotherapy has always been associated with cardiotoxicity. Patients on cardiotoxic drugs can develop a wide range of cardiovascular diseases, including left ventricular (LV) systolic dysfunction and heart failure (HF), arrhythmias, hypertension, and coronary artery disease (CAD). The rising number of cancer patients, population ageing, and the frequent overlap of cardiovascular and oncological diseases have highlighted the importance of close collaboration between cardiologists and oncologists. As a result, in 1995, cardiologists at the IEO (European Institute of Oncology) coined the term cardioncology, a new discipline focused on the dynamics of cardiovascular disease in cancer patients. Given the complex scenario characterized by a constant dialogue between the oncological condition and cardiovascular comorbidity, it is essential for the clinician to get the knowledge to properly fulfill the needs of the oncological patient under cardiotoxic treatment. Through the answer to 10 questions, we aim to describe the complex issue of cardiotoxicity by addressing the main critical points and current evidence related to the assessment, management, treatment, and surveillance of cancer patients under chemotherapy.Keywords
This publication has 45 references indexed in Scilit:
- Pulmonary Vein Isolation for Atrial Fibrillation in the Postpneumonectomy Population: A Feasibility, Safety, and Outcomes StudyJournal of Cardiovascular Electrophysiology, 2015
- Protective Effects of Spironolactone Against Anthracycline-Induced CardiomyopathyEuropean Journal of Heart Failure, 2014
- Evaluation and Management of Patients With Heart Disease and Cancer: Cardio-OncologyMayo Clinic Proceedings, 2014
- Insights Into Onco-CardiologyJACC, 2014
- Asymptomatic Cardiac Toxicity in Long-Term Cancer Survivors: Defining the Population and Recommendations for SurveillanceSeminars in Oncology, 2013
- Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and TrastuzumabCirculation: Cardiovascular Imaging, 2012
- Cardiopulmonary Function and Age-Related Decline Across the Breast Cancer Survivorship ContinuumJournal of Clinical Oncology, 2012
- Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I EvaluationJournal of Clinical Oncology, 2010
- Anthracycline-Induced CardiomyopathyJACC, 2010
- Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose ChemotherapyCirculation, 2004